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Abstract
Bone sarcomas are a clinically and molecularly heter-
ogeneous groupofmalignancies characterized by vary-
ing degrees of mesenchymal differentiation. Despite
advances in medical and surgical management, sur-
vival rates for high-grade tumors have remained static
at 50% to 70%. Tumor stem cells have been recently
implicated in the pathogenesis of other heterogeneous,
highly malignant tumors. We demonstrate here the ex-
istence of a small subpopulation of self-renewing bone
sarcoma cells that are capable of forming suspended
spherical, clonal colonies, also called ‘‘sarcospheres,’’
in anchorage-independent, serum-starved conditions.
These bone sarcoma cells as well as tissue specimens
express activated STAT3 and the marker genes of plu-
ripotent embryonic stem (ES) cells, Oct 3/4 and Nanog.
Expression levels of Oct 3/4 and Nanog are greater in
sarcospheres than in adherent cultures. A subset of
bone sarcoma cells displays several surface markers
of mesenchymal stem cells (Stro-1, CD105, and CD44)
as well as attributes of mesodermal, ectodermal, and
endodermal differentiation. Although previously docu-
mented in brain and breast tumors, our results support
the extension of the cancer stem cell hypothesis to in-
clude tumors of mesenchymal lineage. Furthermore,
they suggest the participation of ES cell homeobox
proteins in non–germ cell tumorigenesis.
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Introduction
Bone sarcomas, including osteosarcoma and chondro-
sarcoma, are among a group of mesenchymal malignancies
that exhibit clinical, histologic, and molecular heterogeneity
[1,2]. Osteosarcoma is the most common primary bone ma-
lignancy of childhood and adolescence, comprising almost
60% of the common histologic subtypes of bone sarcomas
in childhood [3]. Despite advances in surgery and multi-
agent chemotherapy, long-term survival rates have stag-
nated at approximately 65% [4]. Chondrosarcoma, however, is
a disease of adults for which chemotherapy has proven in-
effective. Both tumors metastasize to the lung, and unless lung
metastases can be resected completely, almost all patients
with metastatic bone sarcoma succumb to their disease.
The biology of sarcomagenesis is understood poorly. Recent
studies have implicated stem-like cells in the pathogenesis of
leukemia, brain tumors, and breast tumors [5–8]. The cancer
stem cell theory holds that there is a small subpopulation of cells
within a tumor, which, like normal stem cells, has the ability to
self-renew. These few cells can divide asymmetrically, produc-
ing an identical daughter cell and a more differentiated cell,
which, on subsequent divisions, generates the vast majority
of tumor bulk. This rare stem-like cell is responsible for initiat-
ing and maintaining the growth of the tumor and, if not com-
pletely eradicated by surgical extirpation or chemotherapy,
might be responsible also for local and distant recurrence. For
this study, we hypothesized that the heterogeneity and rela-
tive resistance of bone sarcomas to chemotherapy might be
associated with the presence of tumor stem-like cells. Dem-
onstration of stem-like cells in these tumors would extend
support for the stem cell theory of carcinogenesis from hema-
tologic and ectodermal tumors to mesenchymal tumors [5–9].
Stem cells have the potential to self-renew and generate a
developmental hierarchy of differentiating progeny. The origi-
nal culture methodology employed by Reynolds et al. [10] and
Reynolds and Weiss [11] to show that the adult mammalian
brain contains cells that give rise to neurosphere clones has
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been used to isolate and characterize cells suspected
of possessing attributes of stem and progenitor cells. Stress-
ful growth conditions of this system (serum starvation and
anchorage independence) may allow dedifferentiation of
certain cells, or may select for the most primitive cells by
eliminating the differentiated cells that are unable to survive.
Similarly, suspending dissociated normal and cancerous
tissues in semisolid media without serum selects for primi-
tive clonogenic cells that can be expanded and can give
rise to different classes of cells. We have shown previously
that isolated cells from malignant human brain tumors ex-
hibit a stem cell– like phenotype in a neurosphere culture
system that exploits anchorage independence, serum starva-
tion, and the pleiotropic growth factors epidermal growth
factor (EGF) and basic fibroblast growth factor (bFGF) [7].
Others have further validated this model based on generally
accepted cell surface marker expression, fluorescence-
activated cell sorter isolation and cloning, and reestablish-
ment of tumorigenicity following xenografting [12,13]. Similar
sphere culture systems have been used to identify tumor
stem cells that are capable of self-renewal and tumorigenicity
in mouse models [6,8,9,13] for both brain and breast malig-
nancies. Despite prospective identification of tumor stem
cells by these approaches, molecular mechanisms control-
ling their self-renewal and differentiation are poorly under-
stood. Here, we report the identification of a subpopulation
of stem-like cells in bone sarcomas using a neurosphere cul-
ture system, and we demonstrate that these cells express
the key molecular machinery of embryonic stem (ES) cells.
Materials and Methods
Cell Culture
Osteosarcoma and chondrosarcoma cultures were es-
tablished from patient biopsies. Specimens were minced in
DMEM/F12 medium, digested with 5 mg/ml Collagenase
Type II (Gibco BRL Invitrogen Corporation, Grand Island,
NY) for 3 to 12 hours at 37jC, and passed through a 70-mm
Cell Strainer (BectonDickinson LabWare, Franklin Lakes, NJ)
to prepare a single-cell suspension, as described previously
[7]. Samples were obtained with consent, using protocols
approved by the Institutional Review Board of the University
of Florida College of Medicine. The age range for osteo-
sarcoma patients was 11 to 34 years (median age, 12 years),
whereas that for chondrosarcoma patients was 55 to 67 years
(median age, 57.5 years). Cell cultures 99-1 and 99-2 were
supplied by theUniversity of ColoradoHealth SciencesCenter.
The human osteosarcoma cell line MG 63 was obtained from
the American Type Culture Collection (Rockville, MD). Cells
were cultured in DMEM/F12 medium supplemented with 10%
FBS (HyClone, Logan, UT) at 37jC and 7.0% CO2.
Neurosphere/Sarcosphere System Assays
Cells were plated at a density of 60,000 cells/well in six-
well ultralow attachment plates (Corning Inc., Corning, NY)
in N2 medium with 1% methylcellulose. For this, 2 DMEM/
F12 with progesterone (20 nM), putrescine (100 mM), sodium
selenite (30 nM), transferrin (25 mg/ml), insulin (20 mg/ml;
Sigma Biochemicals, St. Louis, MO), and the growth factors
human EGF (10 ng/ml) and human bFGF (10 ng/ml; Pepro
Tech, Rocky Hill, NJ) were mixed with an equal volume of
2% methylcellulose (Sigma Biochemicals). In addition, fresh
aliquots of EGF and bFGF were added every other day. After
culture for 7 to 12 days, colonies containing more than
50 cells were quantitated by inverted phase contrast micros-
copy (Nikon Eclipse TS100).
Semiquantitative Reverse Transcription Polymerase
Chain Reaction (RT-PCR)
Total RNA was isolated using the RNeasy Mini Kit and
was treated with RNAase-Free DNase (Qiagen Sciences,
Valencia, CA) according to the manufacturer’s instructions.
RNA was quantitated by spectrophotometry at OD260. First-
strand cDNA was made using Oligo(dT)12–18 (Invitrogen Life
Technologies, Carlsbad, CA) primers, 1.5 mg of total RNA,
and SuperScript II RNase H Reverse Transcriptase (Invitro-
gen Life Technologies), according to the manufacturer’s
recommendations. The target cDNA was amplified using
Platinum Taq DNA Polymerase (Invitrogen Life Technolo-
gies) for 35 to 37 cycles at 90jC for 1 minute, at 55 or 60jC
for 30 seconds, and at 72jC for 1 minute. The primers are
provided in Table 1. Aliquots of 8 ml of the amplification prod-
ucts were separated by electrophoresis in 1.2% agarose gels
Table 1. Primer Pairs Used in RT-PCR.
Gene Forward Primer Reverse Primer Product (bp)
Gata-4 GCCCAAGAACCTGAATAAATCTAAG AGACATCGCACTGACTGAGAACGTC 208
Gata-6 TTCCCCCACAACACAACCTACAG GTAGAGCCCATCTTGACCCGAATAC 118
AFP GGTGTAGCGCTGCAAACGATG AATTTAAACTCCCAAAGCAGCACGA 210
STAT3 GGGTGGAGAAGGACATCAGCGGTAA GCCGACAATACTTTCCGAATGC 198
RUNX1 CTCAGGTTTGTCGGTCGAAGTGGAA CCGCAGCTGCTCCAGTTCAC 216
RUNX2 CTCCCTGAACTCTGCACCAAGTCCT GGGGTGGTAGAGTGGATGGACG 156
RUNX3 CCGAGCCATCAAGGTGACCGTGGAC GGGCTGGCTGCTGAAGTGGCTTGT 187
Osteocalcin CCCTCACACTCCTCGCCCTATT AAGCCGATGTGGTCAGCCAACTCGT 259
ALP CACTGCGGACCATTCCCACGTCTT GCGCCTGGTAGTTGTTGTGAGCATA 206
IBSP GGGCAGTAGTGACTCATCCGAAGAA CTCTCCATAGCCCAGTGTTGTAGCA 166
Nanog GCTGAGATGCCTCACACGGAG TCTGTTTCTTGACTGGGACCTTGTC 163
Oct 3/4 TGGAGAAGGAGAAGCTGGAGCAAAA GGCAGATGGTCGTTTGGCTGAATA 186
-III Tubulin CTGCTCGCAGCTGGAGTGAG CATAAATACTGCAGGAGGGC 141
-Actin GCGGGAAATCGTGCGTGACATT GATGGAGTTGAAGGTAGTTTCGTG 229
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and visualized by ethidium bromide staining. Only RNA
samples that gave completely negative results in PCR with-
out reverse transcriptase were used for analyses.
Western Blot Analysis
Cells were lysed in 50 mM Tris–HCl (pH 7.4), 150 mM
NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS, 1% Na-deoxy-
cholate, 1 mM Na-vanadate, and protease inhibitors 5 mg/ml
pepstatin, 1 mM PMSF, 10 mg/ml leupeptin, and 1 mM NaF
(Sigma Biochemicals) for 1 hour in ice. After centrifugation at
12,000g for 10 minutes at 4jC, the protein concentration of
the supernatants was measured by the BCA Protein Assay
kit (Pierce, Rockford, IL). Lysates were mixed (1:1) with
Laemmli buffer (Sigma Biochemicals). Fifteen micrograms
of protein per lane was electrophoresed in 8% to 16% or in
10% to 20% SDS polyacrylamide gels and transferred onto
nitrocellulose membranes (Sigma Biochemicals). Mem-
branes were blocked with nonfat dry milk for 1 hour at room
temperature and incubated overnight at 4jC with the cor-
responding antibodies in 5% bovine albumin (Sigma Bio-
chemicals), Tris-buffered saline (TBS), and 0.1% Tween 20
(Bio-Rad Laboratories, Hercules, CA). After being washed
six times in TBS with 0.1% Tween 20, blots were incubated
with appropriate species: Ig-specific, peroxidase-conjugated
secondary antibodies (Cell Signaling Technology, Beverly,
MA; Jackson Immuno Research Laboratories, West Grove,
PA). ImmunoreactivebandsweredetectedbyECLPlusWest-
ern Blotting Detection Reagents (Amersham Biosciences,
Piscataway, NJ) for 60 seconds. We used primary antibodies
anti-STAT3 (R&D Systems, Minneapolis, MN), phospho-
STAT3 (Tyr705; Cell Signaling Technology), b-III tubulin
(BAbCO, Berkeley, CA), anti–b-actin (Sigma Biochemicals),
alpha fetoprotein (AFP; C-19), and Oct 3/4 (N-19; Santa
Cruz Biotechnology, Santa Cruz, CA).
Immunocytochemistry
Cells were grown for 3 to 5 days on glass coverslips coated
with polyornithine (10 mg/ml)/laminin (5 mg/ml) in DMEM/F12
medium with 10% FBS in 12-well plates. Cells were fixed
in freshly prepared cold 4% paraformaldehyde (Sigma Bio-
chemicals) for 15 minutes at room temperature and made
permeable with ice-cold 0.5% Triton X-100 and 2% sucrose
in Dulbecco’s phosphate-buffered saline (DPBS) for 5 min-
utes. After blocking for 20 minutes with 25% goat serum
(Sigma Biochemicals) in DPBS, cells were incubated for
30 minutes at room temperature in 25% goat serum in
DPBS with primary antibodies b-III tubulin (BAbCO) and
Stro-1 (Developmental Studies Hybridoma Bank, Depart-
ment of Biological Sciences, University of Iowa, Iowa City,
IA) and visualized by indirect immunofluorescence micros-
copy with secondary antimouse antibody. All proteins were
labeled usingAlexa Fluor 594–conjugated antibody (Molecu-
lar Probes, Eugene, OR). For F-actin visualization, cells were
labeled with fluorescein phalloidin.
Histologic Analyses and Immunohistochemistry
Formalin-fixed paraffin-embedded tissue sections (5 mm)
were deparaffinized sequentially, rehydrated, and blocked
for endogenous peroxidase activity. Following a 95jC,
25-minute antigen retrieval in Trilogy unmasking solution
(Cell Marque, Hot Springs, AR), slides were biotin-blocked,
serum-blocked, and immunostained using a goat ABC Elite
Kit (Vector Laboratories, Burlingame, CA). Antibodies to
Oct 3/4 and Nanog (R&D Systems) were applied at 1:50
for 1 hour at room temperature. Positive staining was de-
tected with 3,3V-diaminobenzidene, and light green SF yel-
lowish (Sigma Biochemicals) was used as counterstain.
Differentiation Staining
Cells derived from bone sarcoma spheres were grown on
an adhesive substrate in adipogenic and osteogenic media,
as previously described [14], for 14 days. Lipid-induced cells
were fixed with 10% formalin, washed, and stained with Oil
Red O for 7 minutes. Hematoxylin was used as the counter-
stain. Cells in osteogenic medium were fixed in ethanol,
followed by von Kossa stain and exposure to sunlight for
20 minutes. Cells were washed three times in distilled water
and then counterstained with Nuclear Fast Red.
Statistical Analyses
Statistical analysis was completed using Student’s t tests
to determine the RNA expression difference between adher-
ent and sarcosphere culture conditions for each tumor.
Pearson’s correlation coefficient was performed to compare
the correlation of Oct 3/4 and Nanog coexpression between
sphere and adherent cultures (Statistica; StatSoft, Tulsa, OK).
Results
Sarcosphere Formation and Self-Renewal from
Bone Sarcoma Culture
To determine whether bone sarcomas might contain
stem-like cells, we first established adherent cultures from
biopsies of untreated chondrosarcoma and osteosarcoma,
as well as from the commercially available osteosarcoma
cell line MG 63. We evaluated each for its ability to gener-
ate spherical clones and to self-renew in our neurosphere
culture system. At ~80% confluence, we dissociated these
monolayer cultures into single-cell suspensions and in-
oculated them into a methylcellulose medium without serum,
at a clonogenic density of 60,000 cells/well in antiadhe-
sive six-well plates. It should be noted that these condi-
tions have been optimized to preclude reaggregation of
single cells.
After 10 to 14 days, all nine initial bone sarcoma cul-
tures and the MG 63 cell line formed spherical colonies
(‘‘sarcospheres’’) at an epigenetic frequency of 102 to
103 (Figure 1, A and B). This frequency of sphere forma-
tion is similar to that reported by others for brain and breast
malignancies [6,7,9]. Sarcospheres were also generated
at a similar frequency from fresh tumor dissociates produced
at the time of biopsy (data not shown). This high frequency
suggests an epigenetic mechanism, rather than a mutational
mechanism, underlying these cells’ ability to form clonal col-
onies under our culture conditions.
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We then asked whether clone-forming cells could self-
renew in the sarcosphere system. Cultured sarcospheres
from five representative cultures (osteosarcomas OS 521,
OS 01-187, and OS 99-1, chondrosarcoma CS 828, and os-
teosarcoma MG 63) were dissociated to single cells and
allowed to grow in monolayers. At near-confluence, the cells
were harvested and reseeded as single cells into a suspen-
sion culture, as described above. All five cultures demon-
strated self-renewal through the formation of secondary
spheres at a similar or an increased frequency of approxi-
mately 102. Three of these were recloned serially for four
passages and continued to generate spheres at approxi-
mately the same frequency. These data show that bone
sarcomas share with ectodermal tumors [7,15] the ability
to generate suspended spherical clones under growth-
constraining conditions, and they suggest that they contain
a small subpopulation of self-renewing primitive cells.
Expression of Oct 3/4, Nanog, and STAT3 in Bone
Sarcoma Cells
Pluripotency in embryonic settings is associated with the
ability to maintain the expression of genes specific for mul-
tiple cellular lineages and then to differentiate along one of
those lineages while restricting the others [16]. Current
evidence from murine studies suggests that self-renewal
and pluripotency of undifferentiated ES cells are maintained
by a crosstalk involving three transcription factors: the POU
family member Oct 3/4, the recently identified homeoprotein
Nanog, and activated STAT3 [17,18]. To determine whether
the genes for these proteins are expressed in bone sarcoma
cultures in both sphere and adherent conditions, we first per-
formed semiquantitative RT-PCR analyses.
As shown in Figure 2A, detectable levels of mRNA
were present in each culture type for all three transcription
factors. Both spheres and adherent cultures demonstrated
similar robust levels of STAT3 mRNA. Strikingly, sarco-
spheres grown in the serum-starved, anchorage-independent
system showed significantly greater (P < .05) expression of
both Oct 3/4 and Nanog than cells grown in adherent culture
supplemented with serum (Figure 2, A and B). To determine if
these genes were expressed at the protein level, a series of
Western blot and immunohistochemical analyses was per-
formed. Unfortunately, despite numerous attempts, we were
able only to isolate usable protein from the adherent cultures
and not from spheres in methylcellulose culture. However, as
shown in Figure 2C, in the adherent cultures, we were able to
detect specific immunoreactive species that corresponded in
size with Oct 3/4. We also detected STAT3 and its activated
form, represented by phosphorylation at Tyr705, in each of
the cultures examined (Figure 2C). Immunohistochemical
staining of sarcospheres from paraffin sections, however,
enabled the detection of both Nanog and Oct 3/4 in similar
patterns (Figure2D). Interestingly, the smaller immature
spheres showed a greater proportion of cells that stained
positive for Oct 3/4 and Nanog than did the larger spheres.
Typical of that shown in the figure, the cells in the periphery of
the spheres showed a more intense staining than the internal
cells, giving a ring-like appearance.
Following these observations, we addressed whether
Oct 3/4 and Nanog are expressed in actual tumor tissues.
For this, paraffin sections from eight bone sarcoma patients
were evaluated using immunohistochemistry. Nanog and
Oct 3/4 nuclear staining was observed in seven of eight
tumors studied. In each case, as determined by histologic
criteria, the stained nuclei were from malignant cells and
not from infiltrating normal cells (Figure 3). Between tumor
specimens, the number of Oct 3/4– and Nanog-positive cells
varied considerably. Positive Oct 3/4 staining ranged from
a few percentages of the cells in some tumors up to 25%
in others. Nanog staining was also quite variable, ranging
from ~1% of the cells to nearly 50% in certain samples.
Cumulatively, previous data demonstrate the expression of
ES cell–associated gene products in adherent cultures, sar-
cospheres, and tissue sections from bone sarcomas, and
they support the hypothesis that cells in these tumors pos-
sess attributes of stem cells.
Figure 1. Phase contrast images of monoclonal sarcospheres formed from self-renewing cells from bone sarcoma. Monolayer cultures of cells isolated from bone
sarcoma were seeded at clonogenic density into N2 medium with 1% methylcellulose (see Materials and Methods section) and cultured for 10 to 14 days. Under
these conditions, spheres form at a frequency of 1/100 to 1/1000 cells. (A) Representative image of a sarcosphere in the suspension culture. Cells within the
sphere show a compact undifferentiated morphology. (B) Sarcosphere removed from the suspension culture and allowed to attach to a substratum. Adherent cells
can be seen expanding from the sphere.
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Expression of Genes from Multiple Lineages in
Bone Sarcoma Cells
Based on previous findings, we reasoned that if bone
sarcomas express some of the molecular machineries of
ES cells, they might, in addition to mesodermal genes, ex-
press genes from endodermal and ectodermal lineages.
RT-PCR analyses of mRNA from adherent and sarcosphere
cultures of the eight tumors examined previously, plus an ad-
ditional chondrosarcoma culture (CS 828 LM), revealed the
expression of Gata-4, Gata-6, and AFP, which are indicative
of endodermal differentiation. Expression of b-III tubulinRNA,
which is believed to be a marker of neural ectoderm but has
been demonstrated in some poorly differentiated malig-
nancies [19], was seen as well. UsingWestern blot analyses,
expression of AFP and b-III tubulin at the protein level
was demonstrated in each of the seven cultures tested
(Figure 4B). b-III Tubulin was also detected in paraffin sec-
tions of tumors using immunohistochemistry (Figure 4,C and
D) and in cell culture samples using immunocytochemistry
(Figure 4, E and F ).
Bone Sarcoma Cells Have Attributes of Mesenchymal
Stem Cells
Although the bone sarcomas studied here express tran-
scription factors associated with pluripotent stem cells, their
histologic phenotype is, by definition, one of arrested mes-
enchymal differentiation. Therefore, we examined the re-
spective cultures for cells with characteristic bone marrow
stromal cells, also termed mesenchymal stem cells. These
multipotent cells differentiate along mesenchymal lineages,
such as bone, cartilage, fat, and muscle [14,20–22]. Using
immunocytochemistry, we first screened for the expression
of Stro-1, CD44, and CD105, which are cell surface proteins
associated with mesenchymal stem cells [22,23]. Stro-1 has
been shown previously to be expressed in the permanent
osteosarcoma cell line MG 63 [24].
These assays revealed that 2% to 10% of adherent cells
in each of the chondrosarcoma and osteosarcoma cultures
were positive for the Stro-1 surface protein (Figure 5A).
Additionally, CD105 expression was demonstrated in 30%
to 50%—and CD44 expression was demonstrated in 75%
Figure 2. Genes specific to ES cells show increased expression in sphere cultures derived from bone sarcomas. (A) Monolayer and sarcosphere (SP) cultures
initiated from five osteosarcoma (OS) and three chondrosarcoma (CS) biopsies were analyzed for the expression of Oct 3/4, Nanog, and STAT3 using
semiquantitative RT-PCR. b-Actin expression was used as a positive control. Sphere cultures demonstrate increased transcription of both Oct 3/4 and Nanog over
adherent cultures. STAT3 expression was uniform between both culture types. (B) Relative band intensities for Oct 3/4 and Nanog for each culture from (A) were
quantitated by densitometry, normalized relative to b-actin, and plotted on the graph (Oct 3/4, x-axis; Nanog, y-axis). As indicated by the grouping, the sphere
cultures of each sarcoma showed a significantly greater expression of both Oct 3/4 and Nanog than adherent cultures (P < .05, Pearson’s correlation coefficient).
(C) Western blot analysis of lysates from representative bone sarcoma cell cultures for the protein expression of Oct 3/4, STAT3, and activated (phosphorylated, p)
STAT3. b-Actin was used as a positive control for loading, membrane transfer, and immunoblotting. All cultures showed positive staining of protein bands of
appropriate sizes, as indicated. (D) Small (left) and large (right) sarcospheres were embedded in paraffin and stained using immunohistochemistry for Oct 3/4 and
Nanog, as indicated. Small spheres show an intense staining of cells in the periphery (arrows). Large spheres show similar numbers of darkly staining cells
(arrows), with dramatically increased numbers of poorly staining cells in the interior of the sphere.
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to 100%—of the culture cells tested (data not shown).
There were no obvious morphologic differences between
the positive- or negative-staining cells for these three anti-
gens. Next, to determine if cells within the cultures were
indeed multipotent, we attempted to induce adherent cul-
tures of osteosarcoma and chondrosarcoma cells to differ-
entiate along two distinct mesenchymal lineages by culture
in osteogenic and adipogenic media. Similar to that shown
in Figure 5A, within each adherent culture tested, we ob-
served discrete foci of mineralization in cells grown in os-
teogenic medium and also observed fields of lipid-laden
cells in those grown in adipogenic medium. Finally, when
RNA from the respective cultures was examined using
RT-PCR, multiple genes indicative of mesenchymal lineage
were expressed in both adherent cells and sarcospheres
(Figure 5B). Although differences in expression levels were
noted within and among culture types other than alkaline
phosphatase (ALP), which was expressed more highly in
monolayer cells than in sarcospheres, no discernable pattern
was observed.
Discussion
The goal of this study was to determine if bone sarcomas
contain cells with stem-like properties. To this end, we first
demonstrated that a subset of bone sarcoma cells has the
capacity to form sarcospheres and to self-renew in a culture
system previously developed to isolate stem cells from brain
and breast tumors [7,9,11]. This system yielded clonogenic
stem-like cells that have many attributes in common with
both normal stem cells and glioblastoma stem cells. Further-
more, we found cells derived from these tumors that bear
mesenchymal stem cell markers: Stro-1, CD44, and CD105
can be induced to differentiate along at least two mesenchy-
mal lineages. In addition, cultures of cells from bone sarco-
mas express genes associated with all three germ layers
mesoderm, ectoderm, and endoderm. We also have shown
that sarcospheres preferentially express key marker genes
of ES cell pluripotency, Oct 3/4 and Nanog. These proteins
were also seen in paraffin-embedded sarcoma tumor speci-
mens, extending the relevance of these data beyond in vitro
systems. Altogether, these data provide compelling evidence
of the existence of a subpopulation of stem-like cells in
bone sarcomas.
The expression profiling of our sarcoma cultures identified
differences between cells grown as adherent cultures sup-
plemented with serum and those grown as sarcospheres.
The most striking difference between the two was the in-
creased expression of Oct 3/4 and Nanog in sarcospheres.
These proteins were also detected in tumor tissues by
immunohistochemistry. Interestingly, STAT3, which is con-
sidered to be central to the maintenance of the ES cell phe-
notype in mouse cells [16] but not in human cells [25], did not
Figure 3. Immunohistochemical staining for Oct 3/4 and Nanog in sections from tumor biopsies of chondrosarcoma and osteosarcoma. One representative
osteosarcoma (OS 154) and chondrosarcoma (CS 187) and a positive control, human fetal testes, are shown, as indicated. CS 187 shows a single nucleus positive
(brown) for Oct 3/4 and multiple nuclei positive (brown) for Nanog in lung metastasis from a chondrosarcoma. OS 154 sections demonstrate scattered Oct 3/4
nuclear staining and near-complete nuclear Nanog staining in a primary fibular osteosarcoma. Twenty-six-week fetal testes with scattered Oct 3/4 and Nanog
nuclear staining are shown as positive controls.
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differ in expression level between sarcosphere and adherent
cultures. STAT3 has, however, been shown to be highly ex-
pressed in several human malignancies, promoting metas-
tasis, angiogenesis, and immune evasion [26,27], and, thus,
may play a role in bone sarcomas not directly related to ‘‘stem-
ness.’’ To our knowledge, this is the first evidence that con-
stitutively activated STAT3 is present in bone sarcomas [28].
In-depth evaluation of the sarcospheres revealed that,
following seeding as a single-cell suspension, the early small
spheres that arose primarily comprised cells that were posi-
tive for Oct 3/4 and Nanog. As the spheres grew to a larger
size with increasing cell number, immunohistochemical
staining displayed increasingly greater heterogeneity of the
cells, with a lesser percentage expressing these ES cell
markers. These observations suggest a situation where rel-
atively primitive stem-like cells undergo a transition from
symmetric to asymmetric division and thereupon produce
daughter cells of various states of differentiation. Along these
Figure 4. Analyses of bone sarcoma cultures for the expression of genes of endodermal and ectodermal lineages. (A) RT-PCR analyses of adherent and
sarcosphere cultures as described in Figure 1 for the transcription of endoderm-associated genes (Gata-4, Gata-6, and AFP) and the neuroectoderm marker b-III
tubulin. Primers for b-actin were used as positive reaction controls, as indicated. The control lane represents parallel RT-PCR reactions performed without reverse
transcriptase. (B) Western blot analyses for the expression of b-III tubulin and AFP from lysates of adherent cultures are shown in panel A, demonstrating protein
expressions of endoderm and neuroectoderm-associated genes. (C and D) Expression of b-III tubulin in tissue specimens from bone sarcomas as detected by
immunohistochemistry, and in adherent cultures (E and F) as demonstrated by immunocytochemistry. In panels C and D, arrows indicate regions of positive
staining. In panels E and F, areas of b-III tubulin staining are seen in red. Nuclei were counterstained blue using Hoechst’s stain.
Stem-Like Cells in Bone Sarcomas Gibbs et al. 973
Neoplasia . Vol. 7, No. 11, 2005
lines, it is interesting to note that bone sarcomas, which are
considered to be mesenchymal malignancies, were found
to express genes from endoderm and ectoderm lineages, in
addition to mesodermal genes. At this point, we do not know
the position(s) that a bone sarcoma stem cell might occupy
in the stem cell hierarchy. It is possible that the expression
of genes, such as Gata-4 and Gata-6, is a product of dys-
regulated gene expression in the tumor cells. An alternative
explanation is that these genes are indicative of aberrant
pluripotent differentiation of cancer stem cells.
Curiously, despite the expression of endoderm and ecto-
derm genes in cells in culture, the phenotype of the bone
sarcoma in vivo is clearly mesenchymal. Consistent with this,
numerous cells in the tumor cultures that displayed proteins
characteristic of mesenchymal stem cells were identified.
Despite the fact that the respective cultures originated from
Figure 5. Multipotent cells in bone sarcoma and the expression of mesenchymal lineage genes. (A) Immunocytochemical staining for Stro-1, a cell surface marker
of mesenchymal stem cells, in cultures of osteosarcoma (OS 99-1) and chondrosarcoma (CS 828) cells. Positive staining is shown in orange. Counterstaining for
F-actin is seen in green. Following incubation in osteogenic or adipogenic media to induce differentiation along mesenchymal lineages, the respective cultures were
analyzed for mineralization by von Kossa stain or for lipid vacuoles by Oil Red O stain. As shown, both cultures showed focal staining for osteogenic and adipogenic
differentiation. (B) Semiquantitative RT-PCR analyses for the expression of mesenchymal lineage genes in adherent and sarcosphere (SP) cultures from
osteosarcoma (OS) and chondrosarcoma (CS). Reaction products for the respective cultures using primer pairs specific for RUNX2, RUNX3, ALP, osteocalcin (OS
Ca), and bone sialoprotein ( IBSP) are shown, as indicated. Reactions using primer pairs for b-actin were used as positive controls and also to normalize band
intensities between samples. With the exception of ALP, which was preferentially expressed in the adherent cultures, no significant differences were seen between
the different culture types. All genes assayed were expressed at detectable levels in both conditions.
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tumors of distinct mesenchymal phenotypes (osteoblastic
and chondrocytic), it was possible to induce the differentia-
tion of the cells along alternate mesenchymal lineages. This
suggests that bone sarcoma stem cells might arise from cells
at least as primitive as mesenchymal stem cells.
In our studies, we examined cells from distinct bone
sarcomas. Chondrosarcoma is a tumor derived from carti-
lage cells or cartilage precursors and occurs primarily in
middle-aged to older adults. The samples in this study
were obtained from patients with ages ranging from 55 to
67 years. Osteosarcoma is a tumor comprising bone-forming
or osteoblastic cells and primarily occurs in young adults.
Those used in this study were from patients with ages rang-
ing from 11 to 34 years. Despite the divergent origins of
these cancers, the expression profiles and stem-like proper-
ties of the respective cell types were indistinguishable. This
suggests that the cellular machinery responsible for the
maintenance of the cancer stem cell phenotype may likewise
be very similar in these tumors.
Oct 3/4 is a Pou family homeoprotein expressed initially
in the inner cell mass of embryos and is essential for the
maintenance of pluripotency. It is downregulated as devel-
opment progresses and, following implantation of the em-
bryo, is restricted to primordial germ cells [16]. After maturity,
it is seen only in type A spermatogonia. Oct 3/4 has also
been observed in testicular germ cell tumors [29], terato-
carcinomas, and some early progenitor cells [30]. It is not
seen in somatic cells. Recently, Gidekel et al. [29] have
demonstrated that aberrant Oct 3/4 expression contributes
to the neoplastic process in germ cells. In addition, these
authors were able to demonstrate that nonneoplastic cells
engineered to overexpress Oct 3/4 became tumorigenic.
Nanog is a recently identified divergent homeoprotein that can
maintain self-renewal in ES cells independent of leukemia-
inhibitory factor. Overexpression of Nanog is associated
with increased self-renewal capacity [17,18], and its ex-
pression is apparently restricted to ES cells [16], terato-
carcinomas, and germ cell tumors [29]. Similar to Oct 3/4,
expression of Nanog has not been demonstrated in somatic
cells. Although we have not demonstrated a causal relation-
ship between these proteins and the genesis of bone sarco-
mas, given what we know of the role of Oct 3/4 and Nanog in
maintaining stemness in ES cells, they emerge as poten-
tial players in sarcoma stem cell biology. Together, Oct 3/4,
Nanog, and STAT3 are responsible for the maintenance of
the pluripotent state and for ability for self-renewal in murine
ES cells [16]. If they perform similar functions in cancer
stem cells, they could be important molecular targets of
directed therapy.
This study lends further support to the cancer stem cell
hypothesis that a small number of cells within the bulk of
a solid tumor are responsible for the initiation and growth
of malignancy and, furthermore, suggests a possible mech-
anism for this stem cell– like behavior. Assuming that the
cancer stem cell theory [7,13,31] is correct, cytotoxic chemo-
therapeutic agents, developed in part by assessing the gross
response of the tumor mass, may not address this small
proportion of tumorigenic cells. The cancer stem cell theory
could explain the relative resistance of osteosarcoma to
chemotherapy (in which survival of patients treated with
chemotherapy alone is only 20%) [32] and the near-complete
resistance of chondrosarcoma to standard drug therapy. The
novel findings presented here suggest that the transcrip-
tion factors Oct 3/4 and Nanog may be part of a mechanism
by which these cells maintain stemness. Exploring the roles
these genes play, in conjunction with Stro-1 and other sur-
face markers associated with mesenchymal precursors, may
allow us to prospectively identify the tumorigenic cells in
bone sarcomas. Perhaps more importantly, together, they
may serve as potential targets for selective noncytotoxic ther-
apy in bone sarcoma patients, as these tumors are rather
resistant to current therapeutic protocols.
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